Bumetanide in Patients With Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions
Alzheimer Disease
Interventions
DRUG

Bumetanide

Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.

DRUG

Placebo

A placebo has no active properties and is taken orally.

Trial Locations (1)

94305

RECRUITING

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER